MediWound (NASDAQ:MDWD) Stock Price Breaks Below Fifty Day Moving Average – What’s Next?

Shares of MediWound Ltd. (NASDAQ:MDWD) crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $13.21 and traded as low as $12.46. MediWound shares last traded at $12.97, with a volume of 354,543 shares traded.

Key Stories Impacting MediWound

Here are a few of the latest stories about MDWD:

• Positive Sentiment: MediWound said its Phase III VALUE trial of EscharEx® is advancing, with an interim assessment and enrollment completion expected by the end of Q1 2027. Company results and update
• Neutral Sentiment: The company reported a loss of $0.65 per share, narrower than the $0.71 loss analysts expected, but wider than its $0.24 loss a year earlier. The earnings beat offers some support, though the year-over-year deterioration tempers it. Zacks Q3 results
• Negative Sentiment: Third-quarter revenue was $3.57 million, well below the $6.73 million consensus estimate—about a 47% miss. Reports attributed the weakness in part to stalled U.S. government work. Q3 revenue and government work

Analyst Ratings Changes

Several equities analysts have recently weighed in on MDWD shares. TD Cowen reissued a “buy” rating on shares of MediWound in a research report on Thursday, September 24th. Oppenheimer restated an “outperform” rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. Alliance Global Partners reaffirmed a “buy” rating on shares of MediWound in a report on Wednesday, September 16th. Weiss Ratings lowered shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Finally, Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 26th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

MediWound Stock Performance

The firm has a market capitalization of $168.74 million, a price-to-earnings ratio of -7.21 and a beta of 0.07. The company has a fifty day moving average of $13.21 and a two-hundred day moving average of $15.08.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06. The firm had revenue of $3.57 million for the quarter, compared to analyst estimates of $6.73 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. Equities analysts forecast that MediWound Ltd. will post -2.37 EPS for the current year.

Insider Buying and Selling at MediWound

In related news, COO Shmuel Hess sold 3,958 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On MediWound

A hedge fund recently raised its position in MediWound stock. Russell Investments Group Ltd. grew its holdings in shares of MediWound Ltd. (NASDAQ:MDWD) by 750.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 57,494 shares of the biopharmaceutical company’s stock after acquiring an additional 50,732 shares during the quarter. Russell Investments Group Ltd. owned 0.44% of MediWound worth $792,000 at the end of the most recent quarter. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.